Cargando…
Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemia
Nucleophosmin (NPM1) is an abundant nucleolar protein that is implicated in a variety of biological processes and in the pathogenesis of several human malignancies. For hematologic malignancies, approximately one-third of anaplastic large-cell non-Hodgkin’s lymphomas were found to express a fusion b...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997955/ https://www.ncbi.nlm.nih.gov/pubmed/32071709 http://dx.doi.org/10.1177/2040620719899818 |
_version_ | 1783493785810894848 |
---|---|
author | Chen, Yingyu Hu, Jianda |
author_facet | Chen, Yingyu Hu, Jianda |
author_sort | Chen, Yingyu |
collection | PubMed |
description | Nucleophosmin (NPM1) is an abundant nucleolar protein that is implicated in a variety of biological processes and in the pathogenesis of several human malignancies. For hematologic malignancies, approximately one-third of anaplastic large-cell non-Hodgkin’s lymphomas were found to express a fusion between NPM1 and the catalytic domain of anaplastic lymphoma receptor tyrosine kinase. About 50–60% of acute myeloid leukemia patients with normal karyotype carry NPM1 mutations, which are characterized by cytoplasmic dislocation of the NPM1 protein. Nevertheless, NPM1 is overexpressed in various hematologic and solid tumor malignancies. NPM1 overexpression is considered a prognostic marker of recurrence and progression of cancer. Thus, NPM1 abnormalities play a critical role in several types of hematologic malignancies. This has led to intense interest in the development of an NPM1 targeting strategy for cancer therapy. The aim of this review is to summarize present knowledge on NPM1 origin, pathogenesis, and therapeutic interventions in hematologic malignancies. |
format | Online Article Text |
id | pubmed-6997955 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-69979552020-02-18 Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemia Chen, Yingyu Hu, Jianda Ther Adv Hematol Review Nucleophosmin (NPM1) is an abundant nucleolar protein that is implicated in a variety of biological processes and in the pathogenesis of several human malignancies. For hematologic malignancies, approximately one-third of anaplastic large-cell non-Hodgkin’s lymphomas were found to express a fusion between NPM1 and the catalytic domain of anaplastic lymphoma receptor tyrosine kinase. About 50–60% of acute myeloid leukemia patients with normal karyotype carry NPM1 mutations, which are characterized by cytoplasmic dislocation of the NPM1 protein. Nevertheless, NPM1 is overexpressed in various hematologic and solid tumor malignancies. NPM1 overexpression is considered a prognostic marker of recurrence and progression of cancer. Thus, NPM1 abnormalities play a critical role in several types of hematologic malignancies. This has led to intense interest in the development of an NPM1 targeting strategy for cancer therapy. The aim of this review is to summarize present knowledge on NPM1 origin, pathogenesis, and therapeutic interventions in hematologic malignancies. SAGE Publications 2020-02-03 /pmc/articles/PMC6997955/ /pubmed/32071709 http://dx.doi.org/10.1177/2040620719899818 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Chen, Yingyu Hu, Jianda Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemia |
title | Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and
therapeutic targeting of mutant NPM1 in acute myeloid leukemia |
title_full | Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and
therapeutic targeting of mutant NPM1 in acute myeloid leukemia |
title_fullStr | Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and
therapeutic targeting of mutant NPM1 in acute myeloid leukemia |
title_full_unstemmed | Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and
therapeutic targeting of mutant NPM1 in acute myeloid leukemia |
title_short | Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and
therapeutic targeting of mutant NPM1 in acute myeloid leukemia |
title_sort | nucleophosmin1 (npm1) abnormality in hematologic malignancies, and
therapeutic targeting of mutant npm1 in acute myeloid leukemia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997955/ https://www.ncbi.nlm.nih.gov/pubmed/32071709 http://dx.doi.org/10.1177/2040620719899818 |
work_keys_str_mv | AT chenyingyu nucleophosmin1npm1abnormalityinhematologicmalignanciesandtherapeutictargetingofmutantnpm1inacutemyeloidleukemia AT hujianda nucleophosmin1npm1abnormalityinhematologicmalignanciesandtherapeutictargetingofmutantnpm1inacutemyeloidleukemia |